8-K: Myomo Reports Record Third Quarter Revenue, Raises Full-Year Guidance

Myomo announced record third-quarter revenue of $9.2 million, an 81% increase year-over-year, and raised its full-year revenue guidance to $30-31 million.

Summary

• Myomo reported a record third quarter with total revenue reaching $9.2 million, an 81% increase compared to the same period last year.
• Product revenue specifically saw an 83% increase, driven by both higher unit sales and a higher average selling price.
• The company shipped 161 MyoPro units, a 35% increase year-over-year, with an average selling price of approximately $57,200, or $52,700 excluding supplemental insurance payments.
• Myomo's gross margin improved to 75.4%, up from 68.7% in the third quarter of 2023, primarily due to the higher average selling price.
• The company added a record 645 new patients to its pipeline, bringing the total to 1,263, a 21% increase year-over-year.
• Orders and insurance authorizations reached a record 225 units, and the backlog of orders not yet converted to revenue was 316 units.
• Operating expenses increased by 43% to $7.9 million, mainly due to increased payroll and advertising costs.
• The company's net loss for the quarter was $1.0 million, or $0.03 per share, an improvement from the $2.0 million loss in the same quarter last year.
• Myomo has raised its full-year revenue guidance to $30-31 million, up from the previous guidance of $28-30 million.
• The company expects to achieve operating cash flow breakeven and approach Adjusted EBITDA breakeven in the fourth quarter.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to record revenue, improved gross margins, and increased patient pipeline. The raised full-year guidance and the expectation of reaching cash flow breakeven further contribute to the positive outlook. However, the company is still reporting a net loss and has increasing operating expenses, which tempers the sentiment slightly.

Positives

• Myomo experienced significant revenue growth, with an 81% increase in total revenue and an 83% increase in product revenue year-over-year.
• The company achieved a substantial improvement in gross margin, increasing by 670 basis points to 75.4%.
• Myomo saw a significant increase in patient pipeline additions, with a 69% increase year-over-year.
• The company's backlog of orders increased by 71% year-over-year, indicating strong future revenue potential.
• The cost per pipeline add decreased by 25%, indicating improved efficiency in patient acquisition.
• Myomo raised its full-year revenue guidance, reflecting confidence in continued growth.
• The company is targeting operating cash flow breakeven and approaching Adjusted EBITDA breakeven in the fourth quarter.

Negatives

• Operating expenses increased by 43% year-over-year, primarily due to higher payroll and advertising costs.
• The company reported a net loss of $1.0 million for the quarter, although this is an improvement from the $2.0 million loss in the same quarter last year.
• Year-to-date operating loss was $6.0 million, compared with an operating loss of $5.8 million for the same period a year ago.
• Year-to-date net loss was $5.9 million, or $0.16 per share, compared with a net loss of $5.7 million, or $0.21 per share, for the same period a year ago.
• Year-to-date Adjusted EBITDA was $(5.3) million, compared with $(4.9) million for the same period a year ago.

Risks

• The company's ability to obtain sufficient reimbursement from third-party payers is crucial for its financial performance.
• Myomo needs to manage its revenue concentration with Medicare and specific insurance payers.
• The company must maintain normal operations and patient interactions without supply chain disruptions.
• Myomo's dependence on external financing could pose a risk if it does not achieve or maintain cash flow breakeven.
• The company faces competition in a highly competitive and evolving industry.
• General market, economic, environmental and social factors could affect the evaluation, fitting, delivery and sale of its products.

Future Outlook

Myomo expects fourth-quarter revenue to be in the range of $9.5 million to $10.5 million, resulting in full-year revenue of $30 million to $31 million. The company also anticipates achieving operating cash flow breakeven and approaching Adjusted EBITDA breakeven in the fourth quarter.

Management Comments

• Myomo delivered a second consecutive quarter of record financial and operating results as we emphasized outreach and education to the Medicare population regarding the benefits of the MyoPro, as well as an unwavering commitment to efficiency, quality and improving patient outcomes across our organization, said Paul R. Gudonis, Myomo's chairman and chief executive officer.
• Our focus has been on accelerating revenue growth though our direct provider sales channel and laying the groundwork for growth in the O&P channel in 2025 and beyond.
• We are positioned to deliver sequential revenue growth in the fourth quarter due to the strength of our backlog, added Mr. Gudonis.
• We believe our objective of reaching operating cash flow breakeven in the fourth quarter is achievable. We also expect to approach Adjusted EBITDA breakeven in the fourth quarter, said David Henry, Myomo's chief financial officer.
• Moderation in the growth of working capital in the fourth quarter is predicated on minimizing growth in days sales outstanding and receipt of a contractual reimbursement from the landlord for initial costs associated with the lease on our new facility.

Industry Context

Myomo's results reflect a growing demand for wearable medical robotics and the increasing acceptance of such technologies in healthcare. The company's focus on the Medicare population and expansion into the O&P channel aligns with industry trends towards broader accessibility and reimbursement for advanced medical devices.

Comparison to Industry Standards

• Myomo's 81% year-over-year revenue growth in Q3 is significantly higher than the average growth rate for medical device companies, which typically ranges from 5% to 15%.
• Companies like Ekso Bionics and ReWalk Robotics, which also focus on wearable robotics, have reported slower revenue growth in recent quarters, making Myomo's performance stand out.
• Myomo's gross margin of 75.4% is also higher than the industry average for medical device companies, which typically falls between 50% and 70%.
• The company's success in increasing its average selling price (ASP) to $57,200, or $52,700 excluding supplemental insurance payments, demonstrates strong pricing power compared to competitors.
• The 71% increase in backlog indicates a strong future revenue pipeline, which is a positive sign compared to other companies that may be struggling with order fulfillment or demand.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and improved financial outlook.
• Employees may benefit from the company's growth and potential for future success.
• Customers (patients) will benefit from increased access to Myomo's technology.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Myomo will continue to focus on accelerating revenue growth through its direct provider sales channel.
• The company will continue to lay the groundwork for growth in the O&P channel in 2025 and beyond.
• Myomo will work to minimize growth in days sales outstanding and receive a contractual reimbursement from the landlord for initial costs associated with the lease on its new facility.
• The company will hold a conference call to discuss these results and answer questions.

Key Dates

Keywords

Myomo, MyoPro, wearable robotics, medical devices, revenue, gross margin, patient pipeline, backlog, orthotics, prosthetics, Medicare, EBITDA